Is GHK-Cu FDA-Approved? Why the Answer Depends on the Route

No. GHK-Cu, the copper-binding tripeptide, is not an FDA-approved drug by any route. No GHK-Cu drug product has been approved. Its regulatory position is entirely about pharmacy compounding.

There, the answer depends on how it is given. On FDA’s 503A list (dated May 14, 2026), GHK-Cu for non-injectable routes, such as topical use, is on Category 1. Category 1 means FDA is still evaluating the ingredient and compounding may continue meanwhile. GHK-Cu for injectable routes is on no category at all, because that nomination was withdrawn. Neither status is approval.

GHK-Cu’s status changed twice in two weeks in spring 2026. On April 22, 2026, FDA removed GHK-Cu from Category 1 because its nominations had been withdrawn. On May 5, one nominator clarified that it had meant to withdraw only the injectable route and wanted to keep its nomination for non-injectable routes. FDA then added GHK-Cu (except for injectable routes of administration) back to Category 1.

The result is a split that loose summaries miss. "GHK-Cu is on Category 1" is true for topical and other non-injectable forms. It is not true for injection. Summaries written between April 22 and May 5 describe GHK-Cu as removed from Category 1 entirely, so check the date on any source.

FDA states on its 503A list that it intends to consult the Pharmacy Compounding Advisory Committee before the end of February 2027 about possibly adding GHK-Cu to the 503A bulks list. That is the same kind of review that seven other peptides went through in July 2026.

Be clear about what that review can and cannot produce. The committee votes a non-binding recommendation, and any change to the list then needs formal rulemaking. Even a favourable outcome would make GHK-Cu eligible for pharmacy compounding, not FDA-approved. Approval is a separate pathway that requires a sponsor and clinical evidence for a specific finished product.